1. Fuller A, Cai K, Filippou G, Pascart T, Diaz-Torne C, Hensey O, et al.. Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: a qualitative exploration from the OMERACT CPPD working group. Semin Arthritis Rheum. (2021) 51:655–60. doi: 10.1016/j.semarthrit.2021.04.010, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
2. Zhang W, Doherty M, Bardin T, Barskova V, Guerne PA, Jansen TL, et al.. European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis. (2011) 70:563–70. doi: 10.1136/ard.2010.139105, PMID: [PubMed] [CrossRef] [Google Scholar]
3. Resnick D, Pineda C. Vertebral involvement in calcium pyrophosphate dihydrate crystal deposition disease radiographic-pathological correlation. Radiology. (1984) 153:55–60. doi: 10.1148/radiology.153.1.6089266, PMID: [PubMed] [CrossRef] [Google Scholar]
4. Hutton CW, Doherty M, Dieppe PA. Acute pseudogout of the temporomandibular joint: a report of three cases and review of the literature. Rheumatology. (1987) 26:51–2. doi: 10.1093/rheumatology/26.1.51, PMID: [PubMed] [CrossRef] [Google Scholar]
5. Mac LR. On Rheumatism. London, Longman, Brown: Green & Longman; (1842). [Google Scholar]
6. Marson P, Pasero G. Some historical remarks on microcrystalline arthritis (gout and chondrocalcinosis). Reumatismo. (2012) 63:199–206. doi: 10.4081/reumatismo.2011.199, PMID: [PubMed] [CrossRef] [Google Scholar]
7. Adams R. A treatise on rheumatic gout. 2nd ed. London: John Churchill & Sons; (1873). [Google Scholar]
8. Calvé J, Galland M. Sur une affection particulière de la colonne vertrebale simulant le mal de Pott (calcification de nucleus pulposus). J Radiol Electrol Med Nucl. (1922) 6:21–3. [Google Scholar]
9. Mandl F. Zur Pathologie und Therapie der Zwischenknorpelerkrankungen des kniegelenkes. Arch Klin Chir. (1927) 146:149–214. [Google Scholar]
10. Zitnan D, Sitaj S. Chondrocalcinosis polyarticularis (familiaris): roentgenological and clinical analysis. Cesk Rentgenol. (1960) 14:27–34. PMID: [PubMed] [Google Scholar]
11. Sitaj S, Zitnan D, Trnavska Z, Valsik J. Study on familial outbreaks of alkaptonuria and articular chondrocalcinosis. Bratisl Lek Listy. (1962) 42:129–35. PMID: [PubMed] [Google Scholar]
12. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med. (1961) 54:452. doi: 10.7326/0003-4819-54-3-452 [PubMed] [CrossRef] [Google Scholar]
13. McCarty DJ, Kohn NN, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the “Pseudogout syndrome.” I. Clinical aspects. Ann Intern Med. (1962) 56:711. doi: 10.7326/0003-4819-56-5-711 [CrossRef] [Google Scholar]
14. Kohn N, Hughes RE, Jr MCDJ, Faires JS. The significance of calcium phosphate crystals in the synovial fluid of arthritic patients: the “Pseudogout syndrome”. II. Identification of crystals. Ann Intern Med. (1962) 56:738–45. doi: 10.7326/0003-4819-56-5-738 [PubMed] [CrossRef] [Google Scholar]
15. Martel W, Champion CK, Thompson GR, Carter TL. A roentgenologically distinctive arthropathy in some patients with the pseudogout syndrome. Am J Roentgenol. (1970) 109:587–605. doi: 10.2214/ajr.109.3.587, PMID: [PubMed] [CrossRef] [Google Scholar]
16. Resnick D, Niwayama G, Goergen TG, Utsinger PD, Shapiro RF, Haselwood DH, et al.. Clinical, radiographic and pathologic abnormalities in calcium pyrophosphate Dihydrate deposition disease (CPPD): Pseudogout. Radiology. (1977) 122:1–15. doi: 10.1148/122.1.1, PMID: [PubMed] [CrossRef] [Google Scholar]
17. Utsinger PD, Resnick D, Zvaifler NJ. Wrist arthropathy in calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum. (1975) 18:485–91. doi: 10.1002/art.1780180509 [PubMed] [CrossRef] [Google Scholar]
18. McCarty D. Calcium pyrophosphate dihydrate crystal deposition disease −1975. Arthritis Rheum. (1976) 19:275–85. doi: 10.1002/1529-0131(197605/06)19:3+<275::AID-ART1780190702>3.0.CO;2-0, PMID: [PubMed] [CrossRef] [Google Scholar]
19. McCarty DJ. Calcium pyrophosphate dihydrate crystal deposition disease: Pseudogout: articular chondrocalcinosis In: Mccarty D, editor. Arthritis and allied conditions. 9th ed. Philadelphia, PA: Lea & Febiger; (1979). 1276–99. [Google Scholar]
20. Ciricillo SF, Weinstein PR. Foramen magnum syndrome from pseudogout of the atlanto-occipital ligament. Case report. J Neurosurg. (1989) 71:141–3. doi: 10.3171/jns.1989.71.1.0141, PMID: [PubMed] [CrossRef] [Google Scholar]
21. Gomez H, Chou SM. Myeloradiculopathy secondary to pseudogout in the cervical ligamentum flavum. Neurosurgery. (1989) 298:298. doi: 10.1097/00006123-198908000-00024 [CrossRef] [Google Scholar]
22. Coari G, Iagnocco A, Zoppini A. Chondrocalcinosis sonographic study of the knee. Clin Rheumatol. (1995) 14:511–4. doi: 10.1007/BF02208146, PMID: [PubMed] [CrossRef] [Google Scholar]
23. Rothschild B, Yakubov LE. Prospective 6-month, double-blind trial of hydroxychloroquine treatment of CPDD. Compr Ther. (1997) 23:327–31. PMID: [PubMed] [Google Scholar]
24. De la Garza-Montaño P, Pineda C, Lozada-Pérez CA, Camargo-Ibarias K, González-Hernández MF, Avila-Luna A, et al.. Prevalence of chondrocalcinosis in a Mexican tertiary care institution of musculoskeletal disorders. Clin Rheumatol. (2019) 38:2595–602. doi: 10.1007/s10067-019-04614-1, PMID: [PubMed] [CrossRef] [Google Scholar]
25. Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Chondrocalcinosis is common in the absence of knee involvement. Arthritis Res Ther. (2012) 14:R205. doi: 10.1186/ar4043, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
26. Zhang Y, Terkeltaub R, Nevitt M, Xu L, Neogi T, Aliabadi P, et al.. Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing osteoarthritis study. Arthritis Rheum. (2006) 54:3508–12. doi: 10.1002/art.22189, PMID: [PubMed] [CrossRef] [Google Scholar]
27. Ryu K, Iriuchishima T, Oshida M, Kato Y, Saito A, Imada M, et al.. The prevalence of and factors related to calcium pyrophosphate dihydrate crystal deposition in the knee joint. Osteoarthr Cartil. (2014) 22:975–9. doi: 10.1016/j.joca.2014.04.022, PMID: [PubMed] [CrossRef] [Google Scholar]
28. Neame RL, Carr AJ, Muir K, Doherty M. UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis. (2003) 62:513–8. doi: 10.1136/ard.62.6.513, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Ramonda R, Musacchio E, Perissinotto E, Sartori L, Punzi L, Corti MC, et al.. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The pro. V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. (2009) 27:981–4. PMID: [PubMed] [Google Scholar]
30. Hameed M, Turkiewicz A, Englund M, Jacobsson L, Kapetanovic MC. Prevalence and incidence of non-gout crystal arthropathy in southern Sweden. Arthritis Res Ther. (2019) 21:291. doi: 10.1186/s13075-019-2077-6, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
31. Hawellek T, Hubert J, Hischke S, Krause M, Bertrand J, Schmidt BC, et al.. Calcification of the acetabular labrum of the hip: prevalence in the general population and relation to hip articular cartilage and fibrocartilage degeneration. Arthritis Res Ther. (2018) 20:104. doi: 10.1186/s13075-018-1595-y, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Martinon F, Pétrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. (2006) 440:237–41. doi: 10.1038/nature04516 [PubMed] [CrossRef] [Google Scholar]
33. McGonagle D, Tan AL, Madden J, Emery P, McDermott MF. Successful treatment of resistant pseudogout with anakinra. Arthritis Rheum. (2008) 58:631–3. doi: 10.1002/art.23119, PMID: [PubMed] [CrossRef] [Google Scholar]
34. Cheng X, Haggins DG, York RH, Yeni YN, Akkus O. Analysis of crystals leading to joint Arthropathies by Raman spectroscopy: comparison with compensated polarized imaging. Appl Spectrosc. (2009) 63:381–6. doi: 10.1366/000370209787944280 [PubMed] [CrossRef] [Google Scholar]
35. Fuerst M, Lammers L, Schäfer F, Niggemeyer O, Steinhagen J, Lohmann CH, et al.. Investigation of calcium crystals in OA knees. Rheumatol Int. (2010) 30:623–31. doi: 10.1007/s00296-009-1032-2, PMID: [PubMed] [CrossRef] [Google Scholar]
36. Li B, Yang S, Akkus O. A customized Raman system for point-of-care detection of arthropathic crystals in the synovial fluid. Analyst. (2014) 139:823–30. doi: 10.1039/c3an02062b, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
37. Li B, Singer NG, Yeni YN, Haggins DG, Barnboym E, Oravec D, et al.. A point-of-care Raman spectroscopy–based device for the diagnosis of gout and Pseudogout: comparison with the clinical standard microscopy. Arthritis Rheumatol. (2016) 68:1751–7. doi: 10.1002/art.39638, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Zhang W, Doherty M, Pascual E, Barskova V, Guerne PA, Jansen TL, et al.. EULAR recommendations for calcium pyrophosphate deposition. Part II: Management Ann Rheum Dis. (2011) 70:571–5. doi: 10.1136/ard.2010.139360, PMID: [PubMed] [CrossRef] [Google Scholar]
39. Wu Y, Chen K, Terkeltaub R. Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease. RMD Open. (2016) 2:e000339. doi: 10.1136/rmdopen-2016-000339, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
40. Chollet-Janin A, Finckh A, Dudler J, Guerne PA. Methotrexate as an alternative therapy for chronic calcium pyrophosphate deposition disease: an exploratory analysis. Arthritis Rheum. (2007) 56:688–92. doi: 10.1002/art.22389, PMID: [PubMed] [CrossRef] [Google Scholar]
41. Andres M, Sivera F, Pascual E. Methotrexate is an option for patients with refractory calcium pyrophosphate crystal arthritis. J Clin Rheumatol. (2012) 18:234–6. doi: 10.1097/RHU.0b013e3182611471, PMID: [PubMed] [CrossRef] [Google Scholar]
42. Finckh A, Mc Carthy GM, Madigan A, Van Linthoudt D, Weber M, Neto D, et al.. Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial. Arthritis Res Ther. (2014) 16:458. doi: 10.1186/s13075-014-0458-4, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
43. Williams CJ, Qazi U, Bernstein M, Charniak A, Gohr C, Mitton-Fitzgerald E, et al.. Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease. Osteoarthr Cartil. (2018) 26:797–806. doi: 10.1016/j.joca.2018.03.005, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
44. Danino O, Svetit*ky S, Kenigsberg S, Levin A, Journo S, Gold A, et al.. Inhibition of nucleotide pyrophosphatase/phosphodiesterase 1: implications for developing a calcium pyrophosphate deposition disease modifying drug. Rheumatology. (2018) 57:1472–80. doi: 10.1093/rheumatology/key092, PMID: [PubMed] [CrossRef] [Google Scholar]
45. Filippou G, Scirè CA, Damjanov N, Adinolfi A, Carrara G, Picerno V, et al.. Definition and reliability assessment of elementary Ultrasonographic findings in calcium pyrophosphate deposition disease: a study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. J Rheumatol. (2017) 44:1744–9. doi: 10.3899/jrheum.161057, PMID: [PubMed] [CrossRef] [Google Scholar]
46. Filippou G, Scirè CA, Adinolfi A, Damjanov NS, Carrara G, Bruyn GAW, et al.. Identification of calcium pyrophosphate deposition disease (CPPD) by ultrasound: reliability of the OMERACT definitions in an extended set of joints—an international multiobserver study by the OMERACT calcium pyrophosphate deposition disease ultrasound subtask force. Ann Rheum Dis. (2018) 77:annrheumdis-2017-212542–1199. doi: 10.1136/annrheumdis-2017-212542 [CrossRef] [Google Scholar]
47. Pascart T, Norberciak L, Legrand J, Becce F, Budzik JF. Dual-energy computed tomography in calcium pyrophosphate deposition: initial clinical experience. Osteoarthr Cartil. (2019) 27:1309–14. doi: 10.1016/j.joca.2019.05.007, PMID: [PubMed] [CrossRef] [Google Scholar]
48. Cipolletta E, Di Matteo A, Scanu A, Isidori M, Di Battista J, Punzi L, et al.. Biologics in the treatment of calcium pyrophosphate deposition disease: a systematic literature review. Clin Exp Rheumatol. (2020) 79:447–8. doi: 10.1136/annrheumdis-2020-eular.1080 [CrossRef] [Google Scholar]
49. Dumusc A, Pazar Maldonado B, Benaim C, Zufferey P, Aubry-Rozier B, So A. Anakinra compared to prednisone in the treatment of acute CPPD crystal arthritis: a randomized controlled double-blinded pilot study. Joint Bone Spine. (2021) 88:105088. doi: 10.1016/j.jbspin.2020.105088, PMID: [PubMed] [CrossRef] [Google Scholar]
50. Latourte A, Ea HK, Frazier A, Blanchard A, Lioté F, Marotte H, et al.. Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study. Ann Rheum Dis. (2020) 79:1126–8. doi: 10.1136/annrheumdis-2020-217188, PMID: [PubMed] [CrossRef] [Google Scholar]
51. Yang S, Varghese P, Stephenson E, Tu K, Gronsbell J. Machine learning approaches for electronic health records phenotyping: a methodical review. J Am Med Inform Assoc. (2023) 30:367–81. doi: 10.1093/jamia/ocac216, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
52. Tedeschi SK, Cai T, He Z, Ahuja Y, Hong C, Yates KA, et al.. Classifying Pseudogout using machine learning approaches with electronic health record data. Arthritis Care Res. (2021) 73:442–8. doi: 10.1002/acr.24132, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
53. Tedeschi SK, Becce F, Pascart T, Guermazi A, Budzik JF, Dalbeth N, et al.. Imaging features of calcium pyrophosphate deposition disease: consensus definitions from an international multidisciplinary working group. Arthritis Care Res. (2023) 75:825–34. doi: 10.1002/acr.24898, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Abhishek A, Tedeschi SK, Pascart T, Latourte A, Dalbeth N, Neogi T, et al.. The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease. Arthritis Rheumatol. (2023) 75:1703–13. doi: 10.1002/art.42619, PMID: [PMC free article] [PubMed] [CrossRef] [Google Scholar]
55. Pascart T, Robinet P, Ottaviani S, Leroy R, Segaud N, Pacaud A, et al.. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. (2023) 5:e523–31. doi: 10.1016/S2665-9913(23)00165-0, PMID: [PubMed] [CrossRef] [Google Scholar]
56. Sirotti S, Terslev L, Filippucci E, Iagnocco A, Moller I, Naredo E, et al.. Development and validation of an OMERACT ultrasound scoring system for the extent of calcium pyrophosphate crystal deposition at the joint level and patient level. Lancet Rheumatol. (2023) 5:e474–82. doi: 10.1016/S2665-9913(23)00136-4, PMID: [PubMed] [CrossRef] [Google Scholar]
